COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04362969|
Recruitment Status : Not yet recruiting
First Posted : April 27, 2020
Last Update Posted : May 7, 2020
In December 2019, an outbreak of pneumonia of initially unknown cause was detected in Wuhan (Hubei, China), and it was quickly determined that it was caused by a new coronavirus, that is, the SARS-CoV- 2 virus, causing the disease called COVID-19. Since then, the outbreak has spread to 5 continents, affecting 185 countries or regions, with more than 2,500,000 confirmed cases as of April 21, 2020. Ecuador, the 9th country according to territorial extension, and the 7th according to the number of inhabitants in South America, is the 4th country with the highest number of cases in that region of the world, only behind Brazil, Peru and Chile. According to data from the Ministry of Public Health (MSP) of Ecuador, as of April 20, 2020, the National Institute for Public Health Research (INSPI) has registered 33,279 samples, of which 10,128 are positive for SARS-CoV-2. By far, the province of Guayas where Guayaquil is located, the main city in terms of number of inhabitants of the country, is the region with the highest number of affected, with 6921 confirmed cases and 6274 with suspicion.
Given the importance of this infection, the severity in some cases, its rapid distribution, and the differences in the Ecuadorian population with respect to the other countries where infected patients have been reported, the investigators consider that an updated analysis of cases, taking as a reference, patients seen in various hospitals of the city of Guayaquil can help identify the clinical characteristics and severity of the disease.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Clinical Characteristics of Patients With SARS-CoV-2 (COVID-19) Infection in Guayaquil, Ecuador: COVID-EC Study|
|Estimated Study Start Date :||May 2020|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||May 2020|
- Clinical characteristics of patients with COVID-19 [ Time Frame: 4 weeks ]To know the clinical characteristics of patients with COVID-19 treated in hospitals in Guayaquil, Ecuador.
- Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death [ Time Frame: 4 weeks ]Establish the prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death.
- Clinical characteristics of the patients with the worst prognosis [ Time Frame: 4 weeks ]To determine the clinical characteristics of the patients with the worst prognosis.
- Relationship between the different treatments and the prognosis [ Time Frame: 4 weeks ]Relate, at least retrospectively, the relationship that may exist between the different treatments and the prognosis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362969
|Contact: JORGE CARRIELemail@example.com|
|Guayaquil, Guayas, Ecuador|
|Contact: Roberto Muñoz, MD 593999605614|
|Principal Investigator:||JORGE CARRIEL||Hospital Clínico San Carlos, Madrid|